aibioNasdaq files to remove Aditxt common stock from listing
Tickers ADTX
The Nasdaq Stock Market has filed a Form 25 to remove Aditxt's common stock from listing, dated October 7, 2026. The form does not say why Nasdaq acted, and the company reported $268,852 of cash at March 31, 2026.
Key facts
- Company
- Aditxt, Inc. (OTC: ADTX)
- News type
- Listings
- Primary source
- Aditxt, Inc. 25-NSE (2026-10-07)
The notice
The Nasdaq Stock Market LLC has filed a Form 25 notification with the Securities and Exchange Commission to remove the common stock of Aditxt, Inc. from listing and registration on the exchange. The notice is dated October 7, 2026, and is signed for Nasdaq by Aravind Menon, a hearings advisor. It was filed under 17 CFR 240.12d2-2(b), the rule that covers removals started by an exchange rather than by the company.
The notice covers the common stock only, under commission file number 001-39336. It gives the company's address as 11161 Anderson Street in Loma Linda, California. The company's 10-K filed March 31, 2026 gives its headquarters as Mountain View, California.
The reason is missing
The Form 25 does not say why the exchange acted, and it does not give the date on which the removal takes effect. The form says Nasdaq has complied with its own rules to strike the class of securities, but it names no rule or standard that the company failed. The form says nothing about a Nasdaq letter, a hearing decision or a company filing behind the step, so it does not show whether the company failed a listing standard, asked for a hearing or took any other step.
The business
Aditxt was incorporated in Delaware on September 28, 2017. Its 10-K describes an immune-modulation program run through its subsidiary Adimune, formed in January 2023. The lead candidate, ADI-100, is designed to induce tolerance to glutamic acid decarboxylase, an antigen the filing links to type-1 diabetes, psoriasis and some autoimmune diseases of the central nervous system.
The 10-K says all preclinical studies for ADI-100 have been completed. It says a human trial in Stiff Person Syndrome was expected to start in 2026 with 10 to 20 patients, pending review by an institutional review board and the FDA. The primary readouts in those studies are listed as safety and tolerability, and "clinical and immunological signals of tolerance induction." The filing does not describe any efficacy endpoint for that trial. It cites an estimate that Stiff Person Syndrome affects roughly one in one million people, and it also says the preclinical work was done in animal models, not people.
The company says it has held pre-submission meetings with a German regulator and is working with the Mayo Clinic on an investigational new drug package for the FDA. It expected a pre-IND meeting in the second quarter of 2026. The 10-K does not say whether that meeting took place. The 10-K also says the company holds an exclusive worldwide license to the underlying technology from Loma Linda University.
The money
The 10-K reports revenue of $3,195 for 2025, down from $133,985 for 2024. Research and development expense fell to $3.2 million from $10.9 million. The net loss was $43.1 million for 2025, against $40.4 million for 2024. Cash used in operations rose to $25.7 million in 2025 from $16.8 million in 2024.
The company's 10-Q puts cash and cash equivalents at $268,852 at March 31, 2026. That balance is set against the $25.7 million used in operations during 2025, and the Form 25 gives no cash-runway estimate or plan for raising money.
What comes next
The Form 25 gives no effective date for the removal and mentions no appeal. The 10-K's next dated item was a pre-IND meeting with the FDA expected in the second quarter of 2026.